Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous IL-7-expanded HER2-specific CD4+ T cells

A preparation of autologous, interleukin-7 (IL-7)-expanded, human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)-specific, cluster of differentiation 4 (CD4)-positive T lymphocytes, with potential immunostimulating and antineoplastic activities. Autologous HER2-specific CD4+ T cells are expanded ex vivo with IL-7. Upon reintroduction into the patient, the autologous IL-7-expanded HER2-specific CD4+ T cells recognize and stimulate a T-cell-mediated immune response against HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. IL-7 is a cytokine that promotes the proliferation and survival of T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous IL-7 expanded HER2-specific CD4+ T cells
autologous IL-7-expanded HER2-specific CD4+ T lymphocytes
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search